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Abstract 
Mesoporous silica nanoparticles have been reported as suitable drug carriers, but their 
successful delivery to target tissues following systemic administration remains a 
challenge. In the present work, ultrasound-induced inertial cavitation was evaluated as a 
mechanism to promote their extravasation in a flow-through tissue-mimicking agarose 
phantom. Two different ultrasound frequencies, 0.5 or 1.6 MHz, with pressures in the 
range 0.5-4 MPa were used to drive cavitation activity which was detected in real time. 
The optimal ultrasound conditions identified were employed to deliver dye-loaded 
nanoparticles as a model for drug-loaded nanocarriers, with the level of extravasation 
evaluated by fluorescence microscopy. The same nanoparticles were then co-injected 
with submicrometric polymeric cavitation nuclei as a means to promote cavitation 
activity and decrease the required in-situ acoustic pressure required to attain 
extravasation. The overall cavitation energy and penetration of the combination was 
compared to mesoporous silica nanoparticles alone. The results of the present work 
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suggest that combining mesoporous silica nanocarriers and submcrometric cavitation 
nuclei may help enhance the extravasation of the nanocarrier, thus enabling subsequent 
sustained drug release to happen from those particles already embedded in the tumour 
tissue. 
Keywords: Extravasation, Nanoparticle Delivery, Cavitation, Mesoporous Silica 
Nanoparticles. 
Introduction 
Cancer remains one of the leading causes of death in the world.[1] The poor delivery 
and inadequate distribution of cancer therapeutics in tumours is considered to be one of 
the major hurdles yet to be overcome.[2] The use of nanocarriers to transport anticancer 
drugs has been extensively studied in recent years as a promising strategy to address 
this challenge.[3] Drug nanocarriers can provide many advantages, such as improving 
the pharmacokinetic profile of drugs, increasing their circulation times and improving 
their safety profile.[4] Mesoporous Silica Nanoparticles (MSNs) are one of the most 
promising types of nanoparticles for drug delivery, due to their high drug-loading 
capacity derived from their textural properties, such as their high surface area and pore 
volume, their physicochemical robustness and their ease of functionalization with 
different moieties through silanol chemistry, making them a versatile tool that can be 
easily adapted to different specific applications.[5,6] 
The main rationale behind the vast amount of work in nanomedicine is the selective 
accumulation of nanostructures in solid tumours due to their anomalous vasculature 
related to their rapid growth, which constitutes the enhanced permeation and retention 
effect, often referred to as “passive targeting”.[7] Despite all the efforts spent in 
developing the field of nanomedicine, only a few nano-sized drugs have reached clinical 
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application.[8] Furthermore, while these clinically available nano-drugs have 
significantly improved the safety profile compared to previous formulations with the 
same active components, mainly due to preventing the use of toxic excipients, the 
improvement in their efficacy has been modest at best.[9] A recent analysis on the 
accumulation of nanoparticles in tumours has shown that only a small percentage of the 
injected nanocarriers actually reach the target tumour tissue (ca. 0.7 %).[10] Besides, 
there has been no significant improvement in that parameter over the last decades.[10] 
Moreover, the heterogeneity of tumours in different patients, or even on different areas 
of the tumours from the same patient, implies that even the nanoparticles that reach 
them will not be distributed homogeneously. Furthermore, the elevated interstitial 
pressure of solid tumours also limits the penetration of nanoparticles into the tissue.[11] 
Consequently, a more controlled method to deliver cancer nanotherapeutics is 
necessary, while also ensuring a deeper penetration of the nanoformulations to allow 
them to achieve their full therapeutic potential. 
Ultrasound (US) has emerged as a remarkable tool in biomedicine, being used to induce 
drug release from drug carriers,[12–16] to perform thermal ablation therapies[17] and to 
induce reversible opening of the blood-brain barrier,[18] among many other 
applications.[19–21] Ultrasound can be focused in the region of interest deep within the 
body, reducing the intensity of the stimulus applied to surrounding, non-target areas. 
The biological effects of ultrasound can be divided into thermal and mechanical.[17] 
Among those mechanical effects, cavitation is highlighted as one of the most useful 
ultrasound-related phenomena for biomedicine. It can be defined as the formation and 
linear or non-linear oscillation of gas bubbles in a fluid.[22,23] Sustained linear or non-
linear oscillations about an equilibrium bubble radius for many acoustic cycles is 
termed non-inertial cavitation. However, at more elevated pressures for a given 
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ultrasound frequency and bubble size, the bubble grows unstably during ultrasonic 
rarefaction, subsequently collapsing violently during compression under the inertia of 
the surrounding fluid.   
This phenomenon, termed inertial cavitation (IC), has been used to enhance the delivery 
of different therapeutics for cancer therapy.[22,24–26] In this sense, the main strategy 
employed here consists on using cavitation nuclei that reduce the acoustic pressure 
required to induce IC, which implies violent collapse of gas bubbles.[27] Examples of 
such nuclei include micrometric shelled gas bubbles,[22] droplets [28]  or gas-
stabilizing solid nanoparticles.[29,30] Microstreaming, shockwaves and microjets, 
associated with  IC within blood vessels, can propel the therapeutic into the tumour, 
increasing the delivered dosage and favouring a more homogeneous distribution.[31]  
The main objective of the present work is to evaluate in an in vitro tissue mimicking 
flow model the possibility of MSNs to be used both as drug carriers and as nuclei for 
the generation of IC to improve their delivery and penetration. Additionally, the 
combination of MSNs with sub-micron polymeric cup-shaped gas-stabilizing 
sonosensitive particles (SSP)[29,30] to reduce the acoustic pressures required to initiate 
IC is also investigated.  
Experimental section 
Materials. Following compounds were purchased from Sigma-Aldrich Inc.: 
Aminopropyltriethoxysilane (APTES), ammonium nitrate, cetyltrimethylammonium 
bromide (CTAB), sodium hydroxide, tetraethyl orthosilicate (TEOS), fluorescein 
isothiocyanate (FITC), phosphate-buffered solution (PBS), rhodamine B. These 
compounds were used without further purification. UltraPure™ Agarose-1000 
(Invitrogen, Paisley, UK) was also used without further purification. Ultrapure 
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deionized water was obtained using a Millipore Milli-Q plus system (Millipore S.A.S., 
France). 
Characterisation Techniques. The materials were analysed by small angle X-ray 
diffraction (XRD) in a Philips X’Pert MPD diffractometer equipped with Cu Kα 
radiation. Fourier transform infrared (FTIR) spectra were obtained in a Nicolet (Thermo 
Fisher Scientific) Nexus spectrometer equipped with a Smart Golden Gate Attenuated 
Total Reflectance accessory. Transmission electron microscopy (TEM) was carried out 
in a JEOL JEM 2100 instrument operated at 200 kV, equipped with a CCD camera 
(KeenView Camera). The zeta potential and hydrodynamic size of nanoparticles 
determined by dynamic light scattering (DLS) were measured by means of a Zetasizer 
Nano ZS (Malvern Instruments) equipped with a 633 nm “red” laser. N2 adsorption was 
carried out in a Micromeritics ASAP 2010 instrument; surface area was obtained by 
applying the Brunauer–Emmett–Teller (BET) method to the isotherm and the pore size 
distribution was determined by the Barrett–Joyner–Halenda (BJH) method from the 
desorption branch of the isotherm. Mesopore diameter was obtained from the maximum 
of the pore size distribution curve. 
Fluorescence spectrometry was used to determine cargo release by means of a Biotek 
Synergy 4 device (λexc 540 nm, λem 625 nm). Fluorescence microscopy was performed 
in a Nikon Super Inverted Research Microscope (Ti-E). Individual images were taken 
using a 4x objective. 3D image stitching was performed using the software NIS-
Elements Advanced Research (Nikon UK Limited). Nikon filter cubes were used to 
image FITC (filter cube for FITC, Exciter 465–495, Dichroic 505, Emitter 515–555) 
and rhodamine B (filter cube for TRITC, Exciter HQ545/30×, Dichroic Q570LP, 
Emitter HQ620/60 m).  
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Synthesis of Mesoporous Silica Nanoparticles: MSNs were prepared by a modified 
Stöber method, as previously described.[32] Briefly, 1 g of the surfactant CTAB was 
dissolved in 480 mL of deionised (DI) water with 3.5 mL of NaOH 2M in a 1 L round-
bottom flask. The solution was heated up to 80 ºC under magnetic stirring, and the 
temperature was allowed to stabilize for 30 min. 5 mL of TEOS were added at 0.25 
mL/min and the solution was vigorously stirred at 80 ºC for 2 h. The particles were then 
collected by centrifugation and washed with water and ethanol. The surfactant was then 
extracted by ionic exchange by dispersing the particles in 500 mL of NH4NO3 solution 
in 95% ethanol (10 mg/mL) and magnetically stirring them under reflux overnight. The 
nanoparticles were then collected by centrifugation and washed twice with ethanol. The 
resulting solid was dried under vacuum at room temperature. 
FITC-labelled MSNs (FMSNs) were prepared in a similar manner, by conjugating 1 mg 
of FITC with 2.2 µL of APTES in 100 µL of ethanol with magnetic stirring for 2 h. 
That solution was mixed with 5 mL of TEOS and added onto the CTAB solution under 
basic conditions, following the same protocol as described above. 
Loading and release of Rhodamine B in FMSNs: 2 mg of Rhodamine B were dissolved 
in 20 mL of deionised (DI) water. 20 mg of FMSNs were then dispersed in the dye 
solution with the help of an ultrasound bath and the suspension was magnetically stirred 
at room temperature overnight. The dye-loaded particles (FMSN-RhB) were then 
collected by centrifugation and thoroughly washed with DI water before being dried and 
stored at room temperature until further use. 
Rhodamine B release experiments were carried out as follows. A 1 mg/mL suspension 
of FMSN-RhB in water was prepared and 0.5 mL of such suspension were introduced 
in a Transwell® insert (polycarbonate membrane with a pore size of 0.4 µm) placed in a 
12 well plate. 1.5 mL of DI water were placed in the well outside the insert. At 
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predetermined time points, the release media outside the inserts were collected and 
replaced with fresh DI water. The samples were analysed by fluorimetry using a plate 
reader. Release experiments were performed in triplicate.  
Sonosensitive Particles (SSPs): Submicrometric polymeric cups were obtained from 
OxSonics Ltd (Oxford, UK).[30] Degassed DI water was used to dilute a stock solution 
of 25 mg/mL of SSPs to a final concentration of 0.5 mg/mL. The SSPs had a mean 
diameter of 500 nm, with a cavity diameter between 230 and 340 nm.[30] Suspensions 
of both SSPs and FMSNs combined (final concentration of 0.5 mg/mL and 0.2mg/mL, 
respectively) were also prepared employing degassed DI water (FMSN-SSP 
suspension). 
Experimental setup: The experimental setup used in this work had four main 
components: a focused therapeutic ultrasound transducer (FUS), a passive cavitation 
detector (PCD) that is used to passively record the acoustic emissions produced from 
cavitation, the in vitro tissue-mimicking agarose phantom model (with an embedded 1 
mm channel through which the sample can flow) and a conventional ultrasound imaging 
device. The FUS and PCD are fully controlled from custom-made software using 
graphical programming language (LabVIEW, National Instruments, USA). An arbitrary 
waveform generator (33220A, Agilent, USA) was used to create the transmit signal 
which was amplified by a 300W RF power amplifier (A-300, ENI, USA) and sent to the 
FUS via a 50 ohm matching network.  
 1. Focused therapeutic ultrasound: A spherically-focused single-element FUS 
transducer with a centre frequency of 0.5 MHz was used (H107, Sonic Concepts, USA). 
The same transducer driven at its third harmonic through a customized matching 
network was used for the 1.6 MHz experiments. The aperture and the geometric focus 
of the transducer were 64 mm and 60 mm, respectively. The FUS used was previously 
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calibrated in water using a 0.4 mm diameter needle hydrophone (ONDA 1056, Onda 
Corporation, USA). All acoustic pressures reported in this study are in MPa peak 
rarefactional pressures (PRP). For all extravasation experiments, 600 pulses with a pulse 
repetition time (PRT) of 100 ms were employed. Duty cycle was kept at 5 % in all 
cases.   
 2. Passive Cavitation Detector: A single element PCD (V320, Panametrics, 
USA) was coaxially and confocally aligned with the FUS transducer via a central 
circular opening in the FUS. Acoustic emissions arising from cavitation were sensed by 
the PCD as described previously.[33] Here, a 7.5 MHz spherically focused PCD of 
element diameter 12.5 mm and focal length 75 mm was used. The acquired PCD signal 
was filtered using a 5 MHz high pass filter (FILT-HP5-A, Allen Avionics), amplified 5 
times with a low noise amplifier (Stanford Research Systems, SR445A) and recorded 
with a 14-bit PCI Oscilloscope device (PCI-5122, National Instruments, USA) at a rate 
of 100 MHz. The high-pass filter was used to reject strong reflections from the agarose 
phantom at the fundamental frequency (and harmonics due to non-linear propagation of 
the incident beam). The pressure threshold required to initiate cavitation activity was 
determined by 50-cycle FUS excitation pulses that were ramped at small pressure 
increments under constant flow. A typical PCD data trace consisted of an initial ~85µs 
segment (‘background’) that was free of any signal content in the filter pass band, 
followed by scattering and cavitation emissions (‘signal’) whose durations varied with 
drive pulse length. The background and signal segments of each trace were analysed in 
MATLAB (Mathworks, USA) to determine if IC had occurred and the full ensemble of 
PCD traces were reviewed to calculate a probability of cavitation at the prescribed 
ultrasound settings. For this analysis, any harmonic components were removed by post-
processing with a digital comb filter. The identification of IC was based upon 
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broadband spectral elevation in the signal relative to the background. The harmonic-
suppressed traces were deemed to exhibit IC when the mean-squared signal was at least 
10 times larger than the background signal. 
 3. Tissue-mimicking agarose phantom: A degassed biocompatible hydrogel 
composed of 1.25 % (w/v) low melting point ultrapure agarose gel with an embedded 1 
mm channel was created by heating and cooling process.[22] The phantom contained 
three 50 mm long channels which allowed multiple conditions to be tested in the same 
gel, thus minimising variability. A clear and acoustically transparent Mylar film was 
used to isolate the gel from the surrounding water and allow free propagation of 
ultrasound. A low-pulsatility peristaltic pump (Minipulse Evolution, Gilson, USA) was 
used to flow the FMSNs or FMSN-SSP suspension at a constant flow rate of 0.2 
mL/min. The flow rate was chosen to avoid channel rupture and leakage while still in 
agreement with previously published data of tumour perfusion.[34] 
 4. Ultrasound imaging: A Philips iU-22 ultrasound scanner was used to provide 
real-time imaging of the flow phantom during the experiment. A linear L12-5 probe was 
placed at an angle of 60° to the FUS and PCD propagation axis and imaging was done 
at a low mechanical index (MI < 0.05), in order to minimise interference with the 
experiment. The imaging allowed monitoring of the channel and its contents during the 
experiments and provided real-time feedback of the therapeutic process.  
 Experimental Procedure: All experiments were carried out in a large tank filled 
with DI water that was degassed overnight prior to each experiment. With the channel 
filled with air, the FUS was driven in pulse-echo mode using a pulser-receiver 
(DPR300, JSR Ultrasonics, USA) in order to ensure that the FUS and PCD were aligned 
with the middle of the flow channel. The sample was then introduced at a constant flow 
rate and was kept flowing during FUS exposures. Figure 1A shows a schematic 
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representation of the experimental setup. The input voltages to the FUS matching 
network were also recorded and converted to peak negative pressures using previous 
hydrophone calibrations. Focused ultrasound was applied at different positions within 
the channel, while monitoring both the passive cavitation detector data (to detect 
cavitation during the ultrasound exposure) and performing B-mode imaging 
simultaneously. A photograph of the agarose phantom holder and examples of B-mode 
images taken during the experiments can be seen in Figure 1B and 1C, respectively.  
Flow channels were flushed with DI water following ultrasound exposure to remove 
any remaining fluorescent particles. A rectangular prism containing the flow channel, 
approximately 40 mm long, was then excised and placed on a glass microscope slide to 
evaluate nanoparticle extravasation through microscopy (extravasation is here defined 
as any particle fluorescence detected outside the flow channel). 
Results and Discussion 
Nanoparticle delivery experiments were carried out in an in vitro agarose phantom 
model. The agarose gel acts as tumour tissue mimicking material, having a porosity in 
the same range (ca. 500 nm pore size) as the endothelial gaps of the “leaky” tumour 
tissue.[35] 
Cavitation has been previously used to induce the extravasation of nanoparticles to 
tumour tissues.[22,24–26] The main objective of this work is to evaluate in vitro the 
extravasation of MSNs in the presence of acoustic cavitation with or without SSPs. 
Previously dried FITC-labelled MSNs (FMSNs) were dispersed in degassed water at a 
concentration of 200 µg/mL. FMSN suspensions were prepared by placing them in an 
ultrasound bath for 10 seconds 3 times, with gentle stirring after each time. The 
cavitation threshold of the FMSNs suspension under flow through the agarose phantom 
was evaluated at two different frequencies (0.5 and 1.6 MHz) (Figure 2). The duty cycle 
  
11 
 
(DC) in both cases was limited to 5 % in order to minimise ultrasound-induced 
hyperthermia. IC could be detected at both frequencies with those FMSN suspensions 
(and no cavitation could be detected under the applied pressures at any frequency with 
just degassed water). At 0.5 MHz, cavitation was observed at pressures as low as 0.6 
MPa, and a threshold was observed at 2 MPa where sustained cavitation (probability > 
0.7) is achieved. At 1.6 MHz, cavitation was first observed at 1.5 MPa and linearly 
increased to a probability of 0.71 at 4.3 MPa.  
The IC detected with FMSN suspensions could be attributed to air trapped during 
drying process which could be on the surface or inside nanoparticle aggregates.[36] 
FMSN suspensions were evaluated by Dynamic Light Scattering (DLS) to check for 
nanoparticle aggregates (Figure S1). While no significant percentage of nanoparticle 
aggregates could be observed in the number percentage, some aggregates of several 
microns were detected in the intensity percentage (where larger particulates give more 
intense signals). 
Having confirmed the onset of IC when exposing FMSN suspensions to focused US, the 
extravasation and delivery of those FMSNs in the agarose flow phantom model was 
evaluated next. FMSN suspensions flowing through the agarose phantom were exposed 
to focused ultrasound at 0.5 and 1.6 MHz, at two different PRP for each frequency (1 
and 2 MPa or 2 and 4 MPa, respectively). The agarose phantoms were then cut and 
observed under the fluorescence microscope. Figure 3 shows a schematic representation 
of the nanoparticle delivery experiments and representative images of the results. 
Extravasated nanoparticles can be seen as green fluorescent spots in the agarose gel, 
outside the flow channel. As expected, the extravasation of FMSNs was more 
successful at higher pressures for each frequency, particularly once the cavitation 
threshold identified in Figure 2 was crossed. Differences were observed in the 
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extravasation profiles, with 1.6 MHz achieving higher penetration depths but a more 
directional extravasation profile compared to 0.5 MHz, presumably due to the greater 
effect of acoustic radiation force at the higher frequency. The maximum penetration 
depth of FMSNs after focused US exposure under those conditions can be found in 
Figure S2. 
The main rationale behind the use of MSNs in nanomedicine is the possibility of 
including drugs and other small molecules inside their pores to be then released in a 
controlled manner. Our next experiment consisted on evaluating nanoparticle delivery 
in the same model, but using loaded nanoparticles, to see if they could act as drug 
carriers while still being capable of propelling themselves into the tumour when 
insonified. FMSNs were therefore loaded with rhodamine B (FMSN-RhB). The 
successful loading can be observed by the colour change in the material, as well as by 
the FTIR spectrum and small angle XRD patterns (Figure S3). The drastic changes in 
BET surface area (from 1050 m2/g to 560 m2/g) and pore volume further confirm that 
the mesopores of the material have been occupied by rhodamine B. TEM micrographs 
also show that the ordered porosity is maintained after cargo loading and nanoparticle 
washing. Release experiments of the dye from FMSN-RhB show a sustained release of 
the cargo into the aqueous medium (Figure S4). Rhodamine B release followed first 
order kinetics, with a faster initial release followed by a slower release that can last for 
several days, as previously observed for mesoporous drug release matrices.[12,37]  
The cavitation activity of a suspension of FMSN-RhB exposed to 1.6 MHz focused 
ultrasound was also evaluated following the same procedure as had been performed for 
FMSN and is shown in Figure S5. Results are very similar to FMSN indicating that the 
loading of the dye did not affect the cavitation activity of the particle suspensions. The 
size distribution of FMSN-RhB evaluated by DLS was similar to FMSN, with some 
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aggregates being detected only in the intensity percentage distribution (Figure S6). 1.6 
MHz, 4 MPa was chosen for the FMSN-RhB delivery experiments, as the extravasation 
profiles observed at these settings were easier to detect under the microscope. Figure 4 
shows the successful extravasation of the nanoparticles into the agarose gel (green 
fluorescence). The fluorescence of the cargo (red channel) can also be observed, both 
inside the nanoparticles (fluorescent spots colocalizing with the nanoparticles, in the 
green channel), and partially released from the material. This could be explained 
because the gels were cut and imaged shortly after delivery, so the model drug did not 
have enough time to be released and diffuse in the surrounding tissue, as would be the 
case in an in vivo scenario. Dye fluorescence can also be observed around the channel, 
due to the diffusion of fluorophore released during nanoparticle flow through the 
channel.  
These results show the feasibility of using MSNs as carriers of small molecules that 
could be propelled by the application of focused ultrasound through the onset of IC. 
However, the pressures required to induce MSN extravasation and delivery with FUS 
might be too high for the clinical application of this strategy. The use of cavitation 
nuclei has gathered a lot of attention in recent years, since their usage can greatly 
decrease the pressure threshold needed to generate cavitation.[27,38] Among the 
different cavitation nuclei that have been used to enhance drug delivery, submicrometer 
sized particles hold great promise due to their capacity of extravasating along with the 
therapeutic, and further propelling the drug into the tissue of interest. Microbubbles on 
the other hand would be restrained in the vascular compartment and unable to 
extravasate along with the therapeutic being employed.[30] However, combining 
cavitation nuclei directly with an anticancer drug would only provide an initial dose of 
the drug, without establishing a stable concentration of the drug over time. For these 
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reasons, we studied the combination of mesoporous silica nanoparticles with 
submicrometric polymeric cups. In this manner, a lower ultrasound pressure could be 
applied to extravasate MSNs, which would then act as a reservoir of the drug that would 
be released in the tumour area. Figure 5 shows the successful delivery of FMSNs into 
the agarose gel using 1.6 MHz FUS at just 2 MPa of pressure, a pressure which is 
readily achievable clinically without significant bioeffects and at which no 
extravasation had been previously observed in the absence of cavitation nuclei (Figure 
3). The cavitation energy measured with the combination of FMSNs and SSPs greatly 
exceeded the energy reached at double the pressure without SSPs (Figure S7). 
Temperature elevation measurements were also performed with a fine wire 
thermocouple during FUS exposure (1.6 MHz, 4 MPa, 300 pulses, PRT of 100 ms) 
using both water or a SSPs suspension. The temperature increase produced under those 
conditions was negligible, below 1 ºC, indicating that thermal effects were unlikely to 
be the driving cause of any of the observed results (Figure S8). All of these results 
highlight the great potential of the combination of both types of particles for therapeutic 
application in drug delivery. 
Finally, the combination of SSPs and FMSN-RhB shows significant delivery of FMSN-
RhB to the agar gel, using 1.6 MHz US driven at 2 MPa PRP (Figure 6). Rhodamine B 
can be observed both still inside MSN and partially released into the surrounding gel. 
These results can be interpreted as a proof of concept of our approach, co-injecting 
SSPs with loaded MSN. A combination of both materials could be injected in a patient 
and US could be applied in the tumour area, activating SSPs and inducing IC in the 
area, propelling the particles towards the tumour tissue. Thus, drug-loaded MSN would 
be embedded in the tissue, which would then slowly release an anticancer drug close to 
its target cancer cells.  
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Conclusions 
Ultrasound-induced inertial cavitation (IC) has been shown here to enable enhanced 
extravasation of mesoporous silica nanoparticles in an in vitro flow-through agarose 
tissue phantom. Both empty and dye-loaded nanoparticles were shown to extravasate 
into the agarose gel at ultrasound pressures beyond the IC threshold. The combination 
of those nanoparticles with submicrometric cavitation nuclei was demonstrated as a 
much more efficient way of inducing nanoparticle extravasation, decreasing the 
pressure needed to observe the desired extravasation effect by half. A two-stage strategy 
for the combination of both agents therefore emerges: in the initial step, the cavitation 
nuclei will drive nanoparticle extravasation and distribution throughout the tumour 
tissue when activated by focused ultrasound; mesoporous silica nanoparticles embedded 
in the target tissue then slowly release the drug of interest directly in the tumour mass. 
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Figure captions: 
Figure 1. Schematic diagram of the experimental setup and the apparatus, containing 
the focussed ultrasound (FUS)  transducer, passive cavitation detection (PCD) 
transducer, tissue-mimicking agarose phantom and diagnostic ultrasound imaging 
device (A), Photograph of the agarose phantom holder showing the gel with one of the 
three flow channels prepared (B) and B-mode images during experiment (C) showing 
displacement of air by incoming sample (top), channel with sample flowing (center) and 
inertial cavitation happening within the channel (bottom). 
Figure 2. Probability of IC curves of FMSN in degassed water (200 µg/mL) exposed to 
ultrasound at 0.5 or 1.6 MHz. Data are Means ± SD, N=3. 
Figure 3. Scheme of FMSN delivery experiments in the agarose phantom model (A). 
Representative microscopy images of Nanoparticle delivery in the agarose phantom 
model under different different frequency (0.5 or 1.6 MHz) and pressure (1-4 MPa) 
conditions at the same duty cycle (5%) (N=3), showing bright field (left), green 
fluorescence (center) and green fluorescence in a cross section of the flow channel 
(right) (B-F). Scale bars represent 500 µm.  
Figure 4. Representative microscopy images of FMSN-RhB delivery in the agarose 
phantom model without ultrasound (A) or with FUS exposure at 1.6 MHz and 4 MPa 
(B), showing bright field (left), green fluorescence (center) and red fluorescence (right) 
(N=3). Scale bars represent 500 µm. 
Figure 5. Schematic of combining MSNs with SSPs (A). Representative microscopy 
images of nanoparticle delivery in the agarose phantom model (FMSN in combination 
with SSPs), showing bright field (left), green fluorescence (center) and green 
fluorescence in a cross section of the flow channel (right) (B) (N=3). Scale bar 
represents 500 µm. 
Figure 6. Representative microscopy images of dye-loaded nanoparticle delivery in the 
agarose phantom model (FMSN-RhB in combination with SSPs), showing bright field 
(left), green fluorescence (center) and red fluorescence (right) (B) (N=3). Scale bar 
represents 500 µm. 
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Figure 3.
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Figure 5.
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1. Acoustic inertial cavitation induces extravasation of mesoporous silica 
nanoparticles 
2. Submicron cavitation nuclei decreased the pressure needed for extravasation 
3. The combination of both agents emerges as promising for cancer therapy 
 
 
